MARKET

CDXC

CDXC

ChromaDex
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.810
+0.050
+1.81%
Opening 10:01 01/27 EST
OPEN
2.760
PREV CLOSE
2.760
HIGH
2.845
LOW
2.760
VOLUME
21.60K
TURNOVER
--
52 WEEK HIGH
23.66
52 WEEK LOW
2.510
MARKET CAP
191.90M
P/E (TTM)
-6.6087
1D
5D
1M
3M
1Y
5Y
BRIEF-Chromadex Announces Results Of New Pilot Clinical Trial Showing Anti-Inflammatory Effects Of Nicotinamide Riboside (Nr) Supplementation
reuters.com · 2d ago
ChromaDex Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (NR) Supplementation
LOS ANGELES, January 25, 2022--ChromaDex Corp. (NASDAQ:CDXC) today announced results of the 18th clinical trial on its flagship Niagen® (patented nicotinamide riboside, or "NR") ingredient with promising, peer-reviewed findings reported in the Journal of C...
Business Wire · 2d ago
We Think ChromaDex (NASDAQ:CDXC) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Simply Wall St. · 5d ago
ChromaDex Shares Gain On Niagen Supply Pact With US-Based Provider Of Dietary Supplements
ChromaDex Corp (NASDAQ: CDXC) has 
Benzinga · 6d ago
ChromaDex in pact with Designs for Health to offer new Niagen-formulated products
ChromaDex (NASDAQ:CDXC) is trading ~2.5% higher in the pre-market after announcing a supply agreement with Designs for Health to offer new products formulated with Niagen. Accordingly, Designs for Health, a U.S.-based supplier
Seekingalpha · 01/20 12:14
BRIEF-Chromadex And Designs For Health Partner For New Product Development On Niagen®
reuters.com · 01/20 11:36
ChromaDex and Designs for Health Partner for New Product Development on Niagen®
LOS ANGELES, January 20, 2022--ChromaDex Corp. (NASDAQ:CDXC) today announced a supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners (HCPs). ChromaDex’s proprietary healthy aging ing...
Business Wire · 01/20 11:33
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday morning saw 454 companies set new 52-week lows.
Benzinga · 01/18 15:59
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CDXC. Analyze the recent business situations of ChromaDex through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
60.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CDXC stock price target is 14.80 with a high estimate of 17.00 and a low estimate of 12.00.
High17.00
Average14.80
Low12.00
Current 2.815
EPS
Actual
Estimate
-0.10-0.08-0.05-0.03
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 113
Institutional Holdings: 21.25M
% Owned: 31.12%
Shares Outstanding: 68.29M
TypeInstitutionsShares
Increased
32
1.21M
New
6
67.52K
Decreased
25
581.48K
Sold Out
20
567.63K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.61%
Pharmaceuticals & Medical Research
+1.68%
Key Executives
Chairman/Executive Director
Frank Jaksch
Chief Executive Officer/Director
Robert Fried
Chief Financial Officer
Kevin Farr
Chief Marketing Officer
Fadi Karam
General Counsel/Secretary
Lisa Harrington
Lead Director/Independent Director
Kurt Gustafson
Independent Director
Jeffrey Baxter
Independent Director
Stephen Block
Independent Director
Caroline Levy
Independent Director
Gary Ng
Independent Director
Steven Rubin
Independent Director
Wendy Yu
No Data
About CDXC
ChromaDex Corp. is a global bioscience company, which is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. NAD+ is a coenzyme and a regulator of cellular metabolism. It operates through three segments: Consumer products, Ingredients, and Analytical reference standards and services segment. The Consumer products segment provides finished dietary supplement products that contain the ingredients directly to consumers as well as to distributors. The Ingredients segment develops and commercializes ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Analytical reference standards and services segment supplies phytochemical reference standards and other research and development services. Its ingredients include Tru Niagen and Immulina. The Tru Niagen is a form nicotinamide riboside (NR). NR is a member of the vitamin B3 family. Immulina is a spirulina extract.

Webull offers kinds of Chromadex Corp stock information, including NASDAQ:CDXC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDXC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CDXC stock methods without spending real money on the virtual paper trading platform.